ResearcherTianjin Medical UniversityActive in the last 2 years

HaiTao Wang

Provisional: name at one institution (moderate confidence)As of 13 November 2026

Known by name at one institution; no external author ID yet. Name as it appears in ClinicalTrials.gov.

Their work

Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.

Pancreatic cancer papers: 0
Pancreatic cancer trials: 2 (principal investigator on 1)
Pancreatic cancer grants: 0
Collaborators: 1

Papers, trials and grants by year

2022: 1 trial · 2023: none · 2024: none · 2025: 1 trial

Trials 2

Organoid Drug Sensitivity-Guided Therapy for Refractory Tumors Study chair NCT07906301 ↗
Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors Principal investigator NCT06022276 ↗

Closest collaborators

The 1 strongest of 1 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Lili Wang · 1 shared trial, 2025
- Trial Organoid Drug Sensitivity-Guided Therapy for Refractory Tumors NCT07906301 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.